Erratum. Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen Diabetes Care 2025;48:1607-1611.

This isn't actually a research paper about GLP-1 or obesity treatment - it's what's called an 'erratum,' which is essentially a correction notice published by a medical journal. Think of it like when a newspaper runs a correction the next day to fix a mistake in yesterday's edition. In this case, the journal Diabetes Care is correcting the institutional affiliation listed for one of the authors (Assaf Buch) in a previously published study about semaglutide dosing strategies. The original study compared two different ways of starting patients on semaglutide - a gradual 16-week approach versus the standard 8-week titration - but this erratum contains no information about those actual research findings.

No statistics are provided in this erratum. This is purely an administrative correction to fix author affiliation information that was incorrectly published in the original research paper.